EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Alzheimer’s disease in the era of precision medicine: Advances in pathogenesis, biomarkers, and therapeutics

Jamuna Das, Bhavikkumar Maheshbhai Patel, Jitendriya Biswal, Suvendu Narayan Mishra

Odisha Journal of Psychiatry · 2025

DOI: 10.4103/ojp.ojp_12_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Odisha Journal of Psychiatry, 2025. Verfasst von Jamuna Das und 3 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alzheimer’s disease (AD), the leading cause of dementia, involves progressive cognitive decline and complex pathology, including amyloid-β (Aβ) accumulation, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, mitochondrial deficits, and genetic risk factors. Despite extensive research, disease-modifying therapies remain limited, and early diagnosis is challenging. OBJECTIVE: This review synthesizes advances in AD pathogenesis, diagnostic biomarkers, and therapeutic strategies, with a focus on precision medicine approaches. METHODOLOGY: PubMed, Scopus, Web of Science, and Cochrane Library were searched for studies published from January 2014 to May 2025. Eligible sources included original research, reviews, systematic reviews, meta-analyses, and clinical trial reports addressing AD mechanisms, biomarkers, imaging, or therapies. Two reviewers independently screened and extracted data. RESULTS: From over 250 records, 53 studies were included. Findings reinforce the amyloid–tau–neuroinflammation triad, with synaptic loss most closely linked to cognitive decline. Diagnostic progress includes amyloid/tau positron emission tomography, advanced magnetic resonance imaging, and novel CSF/plasma biomarkers (p-tau181, p-tau217), enabling earlier and more accurate detection. Current symptomatic treatments (cholinesterase inhibitors, memantine) remain standard. Anti-amyloid monoclonal antibodies (aducanumab, lecanemab, and donanemab) effectively reduce plaques but demonstrate mixed cognitive benefits. Ongoing trials are evaluating therapies targeting tau, neuroinflammation, mitochondrial dysfunction, and lifestyle-based interventions. Precision medicine strategies incorporating biomarkers and genetic profiles are increasingly informing trial design. CONCLUSIONS: Advances in molecular diagnostics and targeted therapeutics represent meaningful progress but yield modest clinical benefits. Earlier, multi-targeted and personalized strategies supported by adaptive clinical trials and equitable access are essential to altering the course of AD.

Zitieren

APA

Das, J., Patel, B. M., Biswal, J., & Mishra, S. N. (2025). Alzheimer’s disease in the era of precision medicine: Advances in pathogenesis, biomarkers, and therapeutics. Odisha Journal of Psychiatry. https://doi.org/10.4103/ojp.ojp_12_25

Vancouver

Das J, Patel BM, Biswal J, Mishra SN. Alzheimer’s disease in the era of precision medicine: Advances in pathogenesis, biomarkers, and therapeutics. Odisha Journal of Psychiatry. 2025. doi:10.4103/ojp.ojp_12_25

BibTeX
@article{Das2025,
  author = {Das, Jamuna and Patel, Bhavikkumar Maheshbhai and Biswal, Jitendriya and Mishra, Suvendu Narayan},
  title = {Alzheimer’s disease in the era of precision medicine: Advances in pathogenesis, biomarkers, and therapeutics},
  journal = {Odisha Journal of Psychiatry},
  year = {2025},
  doi = {10.4103/ojp.ojp_12_25}
}
Kostenlos starten →